Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals ltd - aztreonam - pdr for soln inj/inf - 500 milligram

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - aztreonam -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - aztreonam -

Stati Uniti - Ingliż - NLM (National Library of Medicine)

cardinal health - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

remedyrepack inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

rebel distributors corp - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - zyvox formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see precautions, pediatric use and dosage and administration and clinical studies ). linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected (see warnings ). vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia. (see clinical studies ) nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant strains), or streptococcus pneumoniae (including multi-drug resistant strains [mdrsp]). complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant strains), streptococcus pyogenes, or streptococcus agalactia

Stati Uniti - Ingliż - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid tablets are not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus py

Stati Uniti - Ingliż - NLM (National Library of Medicine)

american health packaging - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

apotex corp. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or strept

Stati Uniti - Ingliż - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or strept